Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
SARS-CoV-2 (COVID-19) Severe Pneumonia
Clinical Trial
NCT04412668Last updated: 12/4/2025
LIFE
aTyr Pharma, Inc.